Who is sponsoring NCT04275349?

NCT04275349 is sponsored by Dongzhimen Hospital, Beijing.

What drugs are being tested in NCT04275349?

Interventions in NCT04275349: Xingnaojing injection within 24 hours of symptom onset.

What condition does NCT04275349 study?

NCT04275349 studies Stroke, Acute Ischemic Stroke, Acute Intracranial Hemorrhage.

Is NCT04275349 still recruiting?

NCT04275349 is currently status unknown. Last updated 9 June 2020.

Last reviewed 2020-06-09 · How we verify

NCT04275349: TRACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of pRehospital Intervention With trAditional Chinese Medicine for Acute strokE: A Mixed Methods Research

Status unknown Last updated 9 June 2020

What this trial tests

trial testing Xingnaojing injection within 24 hours of symptom onset in Stroke in 1,000 participants. Status unknown.

Timeline

20 March 2020

Primary endpoint
1 December 2020

1 December 2020

Quick facts

Lead sponsor	Dongzhimen Hospital, Beijing
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	20 March 2020
Primary completion	1 December 2020
Estimated completion	1 December 2020
Sites	1 location across China

Drugs / interventions tested

Xingnaojing injection within 24 hours of symptom onset — full drug profile →

Conditions studied

Stroke — all drugs for Stroke →
Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Acute Intracranial Hemorrhage — all drugs for Acute Intracranial Hemorrhage →

Sponsor

Dongzhimen Hospital, Beijing

Who can join

18 and older, any sex, with Stroke or Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Early neurological deterioration（change between baseline and 3 days)
Time frame: 3 days
The early neurologic deterioration is defined as an increase of 1 points or more in the National Institute of Health Stroke Scale (NIHSS) score between baseline and 3 days. The NIHSS score ranges from 0 (best score) to 42 (worst score).

Sponsor's own description

The main purpose of this trial is to observe whether Xingnaojing, intravenously administered within 24 hours of symptom onset on pre-hospital emergency ambulance, improves the Early neurological deterioration of acute stroke at 3 days.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Chinese Herbal Medicine Xingnaojing Injection for Acute Ischemic Stroke: An Overview of Systematic Reviews and Meta-Analyses.
Tian ZY, Feng LD, Xie Y, Xu DH, et al · · 2021 · cited 26× · PMID 34084137 · DOI 10.3389/fphar.2021.659408
Trial of a prehospital intervention with traditional Chinese medicine for acute stroke (TRACE): Protocol for a mixed-methods research study.
Chen Y, Tian Z, Wang S, Liu H, et al · · 2022 · cited 1× · PMID 36105230 · DOI 10.3389/fphar.2022.879282

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other Dongzhimen Hospital, Beijing trials

Trials by the same sponsor.

NCT07271732 — Songling Xuemaikang Capsules for Cerebral Small Vessel Disease · NA · not yet recruiting
NCT07342075 — Registry Study of Cerebral Small Vessel Disease · recruiting
NCT07163702 — Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke · Phase 2 · not yet recruiting
NCT06857487 — Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke · Phase 1, PHASE2 · recruiting
NCT06933238 — Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04275349 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dongzhimen Hospital, Beijing
Last refreshed: 9 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04275349.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing